Tenecteplase Is Reasonable Alternative to Alteplase for Ischemic Stroke
By Elana Gotkine HealthDay Reporter
MONDAY, March 24, 2025 -- For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes, according to a study published online March 12 in JAMA Network Open.
Justin F. Rousseau, M.D., from the University of Texas Southwestern Medical Center, and colleagues compared short-term effectiveness and safety outcomes for patients with ischemic stroke treated with intravenous tenecteplase versus alteplase in a comparative effectiveness study using data collected from July 1, 2020, through June 30, 2022. The primary end point was functional independence on discharge.
Data were included for 79,550 patients treated with intravenous thrombolysis, of whom 11.9 and 88.1 percent received tenecteplase and alteplase, respectively. The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates, including functional independence at discharge, symptomatic intracranial hemorrhage, and in-hospital mortality or hospice discharge. Among patients who were eligible for but did not undergo endovascular thrombectomy, significant improvement with tenecteplase was seen in discharge home, in-hospital mortality, and composite in-hospital mortality or hospice discharge.
"As the adoption of tenecteplase increases across stroke center types, geographic regions, and stroke characteristics, future research will provide additional insight into whether small but clinically important differences in outcomes between tenecteplase and alteplase exist," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Shorter Leukocyte Telomere Length Linked to Higher Incidence of Age-Related Brain Diseases
THURSDAY, June 12, 2025 -- Individuals with shorter leukocyte telomere length (LTL) have a higher incidence of stroke, dementia, and late-life depression (LLD), individually and...
Talking Therapy Reduces Depression, Anxiety Symptoms in Stroke Survivors
THURSDAY, June 12, 2025 -- For stroke survivors, talking therapy is associated with moderate reductions in depression and large reductions in anxiety symptoms, according to a...
P2Y12 Inhibitor Monotherapy Beneficial for Patients Who Undergo PCI
FRIDAY, June 6, 2025 -- For patients who undergo percutaneous coronary intervention (PCI) and discontinue dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy is...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.